Antiadrenergic Therapy of Chronic Heart Failure
2003; Lippincott Williams & Wilkins; Volume: 107; Issue: 8 Linguagem: Inglês
10.1161/01.cir.0000054530.87613.36
ISSN1524-4539
Autores Tópico(s)Receptor Mechanisms and Signaling
ResumoHomeCirculationVol. 107, No. 8Antiadrenergic Therapy of Chronic Heart Failure Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBAntiadrenergic Therapy of Chronic Heart FailureSurprises and New Opportunities Michael Bristow Michael BristowMichael Bristow From the University of Colorado, Denver. Originally published4 Mar 2003https://doi.org/10.1161/01.CIR.0000054530.87613.36Circulation. 2003;107:1100–1102The great British-American scientist-philosopher Alfred North Whitehead divided progress into three stages, the second of which was termed precision, in which the "right ways and wrong ways" of an original idea are elucidated.1 During this period, reinterpretation of the basic idea occurs and is essential to progress. Whitehead's message is that important ideas are dynamic instruments that are constantly changing as new and usually unexpected information becomes available. This is why tests of particular hypotheses, including those tested in Phase III clinical trials, are often unsupportive, and why therapeutic paradigms constantly change. Within such an ephemeral milieu, the key to ultimate success is to view each unexpected or negative result as an opportunity for constructing and testing even more novel and valuable hypotheses within the framework of the general idea, to ascend to the final stage where progress can be "generalized."1Whitehead's philosophical legacy is impressively in play in the area of antiadrenergic therapy of chronic heart failure (CHF). The unarguable basic idea is that the biologically powerful adrenergic compensatory mechanism plays a critical role in the natural history of CHF. It is the details or nuances within the general paradigm that continue to change, and lately, surprisingly so. As recently reviewed,2 the importance of dysfunctional adrenergic activation in CHF was first elucidated by work performed by Braunwald's group at the National Institutes of Health in the 1960s. Among other things, this early work provided the first evidence of marked adrenergic activation in CHF. However, on the basis of reduction in myocardial tissue norepinephrine, and the short-term effects of large doses of antiadrenergic agents,3 the overall interpretation was that adrenergic support was deficient in CHF. This view prevailed for 10 to 15 years, and it contributed to the original logic behind developing Type III phosphodiesterase inhibitors as a treatment for CHF. In the late 1970s and early 1980s, three separate lines of evidence contributed to a 180-degree turn in the role of adrenergic mechanisms in CHF. As recently summarized,4 these paradigm-changing observations were: (1) the apparently favorable clinical response to β-blocking agents when administered chronically to subjects with idiopathic dilated cardiomyopathies; (2) the evidence that the failing human heart exhibited β-adrenergic receptor downregulation and pathway desensitization, which are typical responses to excessive exposure to adrenergic drive; and (3) the demonstration that coronary sinus norepinephrine levels were elevated in CHF patients, reflecting an increase in interstitial levels despite the decrease in tissue stores. For the next 15 to 20 years, the prevailing view was that excessively and incessantly increased adrenergic drive is uniformly harmful to the natural history of primary or secondary dilated cardiomyopathies and to the CHF clinical syndrome.4 This refinement predicts that any treatment that reduces adrenergic activation would produce favorable effects on CHF natural history.However, results of recently completed clinical trials are not consistent with this general paradigm. An agent that powerfully lowers norepinephrine through central imidazoline and/or α2-adrenergic receptor activation plus possible presynaptic α2-receptor agonism, moxonidine, increased mortality by >50% in the Moxonidine Congestive Heart Failure (MOXCON) Trial, with the study being terminated for safety concerns after ≈1000 patients were enrolled.5 In phase II this compound was powerfully sympatholytic, and the degree of systemic norepinephrine reduction was directly associated with an increase in serious adverse events despite evidence for reverse remodeling, the signature of favorable antiadrenergic effects on the failing heart.6 Because sympatholysis is the only known important pharmacological property of moxonidine, these data seriously challenged the uniform dogma that antiadrenergic therapy is beneficial. That sympatholysis is a harmful pharmacological property in a therapeutic agent used to treat CHF is further supported by data from the β-Blocker Evaluation of Survival (BEST) Trial, in which the unique β-blocker/sympatholytic agent bucindolol increased mortality in 14% of the treated population through a pronounced sympatholytic effect that was not observed in placebo-treated patients.7 The BEST Trial was stopped for benefit in the majority of the study population examined (non-black New York Heart Association Class III), with the degree of mortality reduction consistent with the results of other large β-blocker trials just reported in these populations.8,9 In addition, in the entire BEST cohort, nearly all secondary end points were favorably affected by bucindolol.8 Dilution of efficacy to a statistically insignificant reduction (by 10%) in mortality in the larger cohort of BEST was due to the lack of efficacy in Class IV and black patients,8,9 which has in turn been ascribed to the unique sympatholytic properties of bucindolol.7 Therefore, the harmful effects of sympatholysis are observed when a "pure" agent, such as moxonidine, is used to treat advanced heart failure patients, as well as when an otherwise beneficial, mixed action agent, such as bucindolol, is used in subpopulations who are predisposed to adverse effects of adrenergic withdrawal. The likely explanation for the polar difference in the response of these two general classes of antiadrenergic agents is that during the crucial early period of adrenergic inhibition, sympatholytic agents produce an irreversible removal of adrenergic support with the inability to recruit adrenergic drive when needed to support cardiac function. In contrast, β-blockers are mass-action agents whose inhibition can be easily reversed by norepinephrine competition, which allows for the retention and recruitment of the powerful adrenergic support mechanism on an as needed basis. Extensions of these observations include the potentially favorable effects of therapeutic approaches that allow the beneficial aspects of adrenergic inotropic support to be maintained in the presence of β-blockade,10 or the addition to β-blockade of positively inotropic device therapy.Powerful sympatholysis, conferred in a third-generation β-blocker by presynaptic β2-receptor blockade unopposed by potent α-blockade, is unique to bucindolol, and is not present in carvedilol or β1-receptor selective second-generation antagonists.11 Therefore, pharmacological heterogeneity among β-blocking agents can translate into differences in clinical response, in contrast to the rather unvarying pharmacological properties and clinical responses to angiotensin-converting enzyme inhibitors. Another pharmacological property that can influence clinical outcomes is intrinsic sympathomimetic activity (ISA). β1-receptor ISA to the extent possessed by xamoterol is clearly harmful,12 consistent with the myopathic and cytotoxic potential of β1-adrenergic signaling in model myocardial systems. Analogous to work in transgenic models, β1-receptor intrinsic activity appears to be more clinically harmful than β2, because the β2 ISA-containing agent celiprolol is well tolerated in CHF.13 There has been controversy about bucindolol possessing ISA on the basis of evidence of this property in functioning rat myocardium14 and perhaps in nonfunctioning human myocardial tissue cultures.15 However, three independent studies in functioning isolated human nonfailing or failing human myocardial preparations have demonstrated no ISA for bucindolol, even under conditions of augmented signal transduction.16–18 Moreover, in the most sensitive method of ISA detection, Holter Monitoring of 24-hour heart rate, xamoterol, and celiprolol demonstrate ISA, but bucindolol does not.19 In fact, recent data from my laboratory indicate that under well-controlled conditions of augmented signal transduction in functioning isolated human right ventricular preparations, carvedilol, but not bucindolol, exhibits ISA17 (unpublished data). The small amounts of carvedilol ISA detectable in experimental conditions of artificially augmented signal amplification are similar to those recently reported in transgenic mice overexpressing human β1-adrenergic receptors.20 In view of the excellent clinical results with carvedilol, subpharmacological ISA detected by these methods is not likely to produce adverse effects, but it could contribute to the beneficial results of carvedilol.In contrast to the above-noted pharmacological properties that create heterogeneity of response in CHF, blockade of myocardial β1-adrenergic receptors versus additional pathological growth-coupled adrenergic receptor pathways has not produced evidence of the superiority of one approach versus another, for left ventricular functional,21,22 clinical,23 or molecular24 responses. As discussed previously,23 this is likely due to the β1-receptor selectivity of norepinephrine and, to a greater degree of myocardial pathogenicity of the β1 versus β2 or α1-receptor pathways. The soon-to-be reported Carvedilol Or Metoprolol European Trial (COMET) Trial comparing metoprolol to carvedilol should provide the ultimate answer as to whether blockade of additional myocardial adrenergic receptors adds incremental clinical benefit to β1-blockade in CHF.Of major relevance to antiadrenergic strategies in CHF is the recent report by Small et al24 that a double adrenergic receptor polymorphism, an α2C deletion-loss of function genotype (α2CDel322 to 325), combined with a high-functioning β1-receptor genotype (β1Arg389), confers a 10-fold risk for the development of heart failure. The α2C polymorphism likely leads to a reduction in the natural brake on norepinephrine release provided by α2-receptors, and the increased adrenergic drive in these individuals then presumably damages the heart to a greater extent in individuals with the high function β1-receptor polymorphism. Importantly, the α2C polymorphism is enriched in blacks,24 and it provides a potential explanation for certain characteristics of CHF in this population, including worse cardiac function and prognosis per a given degree of functional incapacity. How can this information be reconciled with the antiadrenergic treatment data? Merging of these two bodies of data provides a unique opportunity to tailor antiadrenergic therapy to patient populations who may be more likely to respond, and to move beyond the outdated and soon-to-be economically untenable approach of treating large numbers of patients to capture the minority who actually respond to a specific therapy. For example, the α2C polymorphism subjects may well be the ones in BEST who predisposed bucindolol to the adverse effects in blacks, via exorbitant sympatholysis at a point in the natural history in which their severely failing myocardium had become completely dependent on high levels of adrenergic support. But what if a sympatholytic agent had been given much earlier in these patients' CHF course to prevent the increased potential for adrenergic damage? Moreover, if this were to be combined with β1-receptor blockade in subjects who also possess the β1Arg389 high-functioning β1-receptor polymorphism, then a study in left ventricular dysfunction or mild heart failure might well be able to detect an efficacy signal in a relatively small sample size. It has already been shown that a pharmacogenetic profile can predict response to β-blocking agents,25 and the recent data of Small et al24 suggest that responders to this form of therapy can be even further refined.In summary, recent clinical trial data with antiadrenergic agents in advanced CHF populations reveal a surprisingly marked heterogeneity of clinical response between sympatholytic and β-receptor blocking compounds, with sympatholysis being harmful and receptor blockade being beneficial. These observations nudge current adrenergic theory back toward the original interpretation of the importance of adrenergic support to survival in at least some advanced heart failure patients, and they suggest that more attention needs to be given to the maintenance of such support in the development of the next generation of therapy. Moreover, new information on the effects of adrenergic receptor polymorphisms provides the rationale for pharmacogenetically tailored antiadrenergic therapy, which may include agents that would not be effective in the entire advanced heart failure population.FootnotesCorrespondence to Michael Bristow, MD, PhD, University of Colorado HSC, 4200 E Ninth Ave, B139, Denver, Colorado 80262. E-mail [email protected]References1 Whitehead AN. Whitehead's American Essays in Social Philosophy. Westport, Conn: Greenwood Press; 1975.Google Scholar2 Braunwald EB, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000; 102: 14–23.LinkGoogle Scholar3 Gaffney TE, Braunwald EB. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 1963; 34: 320–324.CrossrefMedlineGoogle Scholar4 Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000; 101: 558–569.CrossrefMedlineGoogle Scholar5 Coats AJ. Heart failure 99: the MOXCON story. Int J Cardiol. 1999; 71: 109–111.CrossrefMedlineGoogle Scholar6 Swedberg K, Bristow MR, Cohn JN, et al, for the MOXSE Investigators. The effects of moxonidineSR, an imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Circulation. 2002; 105: 1797–1803.LinkGoogle Scholar7 Bristow M, Krause-Steinrauf H, Abraham W, et al. Sympatholytic effect of bucindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST. Circulation. 2001; 104: II-755.Google Scholar8 BEST Trial Investigators. A trial of the β-adrenergic blocker bucindolol in patients with advanced heart failure. N Engl J Med. 2001; 344: 1659–1667.CrossrefMedlineGoogle Scholar9 Domanski MJ, Krause-Steinrauf H, Deedwania PC, et al. A comparative analysis of the results of three trials of β-blocker therapy for heart failure: BEST, CIBIS-II, and MERIT-HF. J Cardiac Failure. 2001; 7 (Suppl 3): 56.Google Scholar10 Bristow MR, Shakar SF, Linseman JV, et al. Inotropes and β-blockers: is there a need for new guidelines? J Cardiac Failure. 2001; 7 (2 Suppl 1): 8–12.CrossrefMedlineGoogle Scholar11 Lowes BD, Gilbert EM, Lindenfeld JA, et al. Differential effects of β-blocking agents on adrenergic activity. Circulation. 2000; 102: II-628.Google Scholar12 The Xamoterol in Severe Heart Failure Study Group. Xamatoterol in severe heart failure. Lancet. 1990; 336: 1–6.CrossrefMedlineGoogle Scholar13 Witchitz S, Cohen-Solal A, Dartois N, et al. Treatment of heart failure with celiprolol, a cardioselective β-blocker with β-2 agonist vasodilatory properties: the CELICARD Group. Am J Cardiol. 2000; 85: 1467–1471.CrossrefMedlineGoogle Scholar14 Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther. 1999; 289: 48–53.MedlineGoogle Scholar15 Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002; 105: 2429–2434.LinkGoogle Scholar16 Maack C, Cremers B, Flesch M, et al. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol. 2000; 130: 1131–1139.CrossrefMedlineGoogle Scholar17 Sederberg J, Wichman SE, Lindenfeld J, et al. Bucindolol has no sympathomimetic activity in nonfailing ventricular preparations. J Am Coll Cardiol. 2000; 35: 207A.Google Scholar18 Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001; 133: 1330–1338.CrossrefMedlineGoogle Scholar19 Bristow MR, Roden RL, Lowes BD, et al. The role of third generation β-blocking agents in chronic heart failure. Clinical Cardiology. 1998; 21 (Suppl I): I-3–I-13.Google Scholar20 Engelhardt S, Grimmer Y, Fan GH, et al. Constitutive activity of the human β(1)-adrenergic receptor in β(1)-receptor transgenic mice. Mol Pharmacol. 2001; 60: 712–717.MedlineGoogle Scholar21 Metra M, Giubbini R, Nodari S, et al. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000; 102: 546–551.CrossrefMedlineGoogle Scholar22 Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with β-blocking agents. N Engl J Med. 2002; 346: 1357–1365.CrossrefMedlineGoogle Scholar23 Bristow MR. What type of β-blocker should be used to treat chronic heart failure? Circulation. 2000; 102: 484–486.CrossrefMedlineGoogle Scholar24 Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002; 347: 1135–1142.CrossrefMedlineGoogle Scholar25 McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001; 103: 1644–1648.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Elia A and Fossati S (2023) Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease, Frontiers in Physiology, 10.3389/fphys.2023.1060666, 14 Jiang J, Ni L, Zhang X, Gokulnath P, Vulugundam G, Li G, Wang H and Xiao J (2023) Moderate‐Intensity Exercise Maintains Redox Homeostasis for Cardiovascular Health, Advanced Biology, 10.1002/adbi.202200204, (2200204) Maning J, Desimine V, Pollard C, Ghandour J and Lymperopoulos A (2022) Carvedilol Selectively Stimulates βArrestin2-Dependent SERCA2a Activity in Cardiomyocytes to Augment Contractility, International Journal of Molecular Sciences, 10.3390/ijms231911315, 23:19, (11315) Lin J, Ding L, Xu L, Huang J, Zhang Z, Chen X, Cheng Y, Ruan C and Gao P (2022) Brown Adipocyte ADRB3 Mediates Cardioprotection via Suppressing Exosomal iNOS, Circulation Research, 131:2, (133-147), Online publication date: 8-Jul-2022. Masarone D, Martucci M, Errigo V and Pacileo G (2021) The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction, Journal of Cardiovascular Development and Disease, 10.3390/jcdd8090101, 8:9, (101) Dilger A, Johnson B, Brent P and Ellis R (2021) Comparison of beta-ligands used in cattle production: structures, safety, and biological effects, Journal of Animal Science, 10.1093/jas/skab094, 99:8, Online publication date: 1-Aug-2021. Lymperopoulos A, Cora N, Maning J, Brill A and Sizova A (2021) Signaling and function of cardiac autonomic nervous system receptors: Insights from the GPCR signalling universe, The FEBS Journal, 10.1111/febs.15771, 288:8, (2645-2659), Online publication date: 1-Apr-2021. Cai Y, Liu R, Lu X, Zhang Q, Wang X, Lian H and Wang H (2020) Correlation in gene expression between the aggravation of chronic obstructive pulmonary disease and the occurrence of complications, Bioengineered, 10.1080/21655979.2020.1839216, 11:1, (1245-1257), Online publication date: 1-Jan-2020. Ashraf S, Hegazy Y and Harmancey R (2019) Nuclear receptor subfamily 4 group A member 2 inhibits activation of ERK signaling and cell growth in response to β-adrenergic stimulation in adult rat cardiomyocytes, American Journal of Physiology-Cell Physiology, 10.1152/ajpcell.00526.2018, 317:3, (C513-C524), Online publication date: 1-Sep-2019. Simon K and Wittmann I (2019) Can blood glucose value really be referred to as a metabolic parameter?, Reviews in Endocrine and Metabolic Disorders, 10.1007/s11154-019-09504-0, 20:2, (151-160), Online publication date: 1-Jun-2019. Bendary A, Bendary M and Salem M (2018) Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials, Heart Failure Reviews, 10.1007/s10741-018-9745-5, 24:2, (245-254), Online publication date: 1-Mar-2019. Balligand J (2016) Cardiac salvage by tweaking with beta-3-adrenergic receptors, Cardiovascular Research, 10.1093/cvr/cvw056, 111:2, (128-133), Online publication date: 15-Jul-2016. Alhaj E (2016) Can unilateral adrenalectomy be an option in modulating autonomic nervous system in heart failure?, International Journal of Cardiology, 10.1016/j.ijcard.2016.01.095, 207, (50-52), Online publication date: 1-Mar-2016. Samson R, Baydoun H, Jaiswal A and Le Jemtel T (2015) Cardiac Adrenergic Nervous System and Left Ventricular Remodeling, The American Journal of the Medical Sciences, 10.1097/MAJ.0000000000000549, 350:4, (321-326), Online publication date: 1-Oct-2015. Chatterjee N and Singh J (2015) Novel Interventional Therapies to Modulate the Autonomic Tone in Heart Failure, JACC: Heart Failure, 10.1016/j.jchf.2015.05.008, 3:10, (786-802), Online publication date: 1-Oct-2015. Parajuli N, Ramprasath T, Zhabyeyev P, Patel V and Oudit G (2015) The Role of Neurohumoral Activation in Cardiac Fibrosis and Heart Failure Cardiac Fibrosis and Heart Failure: Cause or Effect?, 10.1007/978-3-319-17437-2_18, (347-381), . Passamani L, Abdala A, Moraes D, Sampaio K, Mill J, Paton J and Singla D (2014) Temporal Profile and Mechanisms of the Prompt Sympathoexcitation following Coronary Ligation in Wistar Rats, PLoS ONE, 10.1371/journal.pone.0101886, 9:7, (e101886) Thoemmes S, Stutzke C, Du Y, Browning M, Buttrick P and Walker L (2014) Characterization and validation of new tools for measuring site-specific cardiac troponin I phosphorylation, Journal of Immunological Methods, 10.1016/j.jim.2013.11.020, 403:1-2, (66-71), Online publication date: 1-Jan-2014. Lymperopoulos A, Rengo G and Koch W (2013) Adrenergic Nervous System in Heart Failure, Circulation Research, 113:6, (739-753), Online publication date: 30-Aug-2013. Marina N, Tang F, Figueiredo M, Mastitskaya S, Kasimov V, Mohamed-Ali V, Roloff E, Teschemacher A, Gourine A and Kasparov S (2012) Purinergic signalling in the rostral ventro-lateral medulla controls sympathetic drive and contributes to the progression of heart failure following myocardial infarction in rats, Basic Research in Cardiology, 10.1007/s00395-012-0317-x, 108:1, Online publication date: 1-Jan-2013. Machida M, Takechi S, Fujimoto T, Kakinoki S and Nomura A (2012) Carvedilol Improves Uptake-1 in Patients With Systolic Congestive Heart Failure, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0b013e31823a94a2, 59:2, (175-181), Online publication date: 1-Feb-2012. Martin M, Belmonte S, Ram R, Kamal F and Blaxall B (2012) G-Protein-Coupled Receptors in the Heart Muscle, 10.1016/B978-0-12-381510-1.00008-9, (87-112), . Jensen B, O'Connell T and Simpson P (2011) Alpha-1-adrenergic receptors: Targets for agonist drugs to treat heart failure, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2010.11.014, 51:4, (518-528), Online publication date: 1-Oct-2011. Damani S and Topol E (2010) Emerging clinical applications in cardiovascular pharmacogenomics, WIREs Systems Biology and Medicine, 10.1002/wsbm.113, 3:2, (206-215), Online publication date: 1-Mar-2011. Bernardo B, Weeks K, Pretorius L and McMullen J (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2010.04.005, 128:1, (191-227), Online publication date: 1-Oct-2010. Panebra A, Wang W, Malone M, Pitter D, Weiss S, Hawkins G, Liggett S and Schwartz A (2010) Common ADRB2 Haplotypes Derived from 26 Polymorphic Sites Direct β2-Adrenergic Receptor Expression and Regulation Phenotypes, PLoS ONE, 10.1371/journal.pone.0011819, 5:7, (e11819) Dorn G (2010) Adrenergic Signaling Polymorphisms and Their Impact on Cardiovascular Disease, Physiological Reviews, 10.1152/physrev.00001.2010, 90:3, (1013-1062), Online publication date: 1-Jul-2010. Konhilas J (2010) What We Know and Do Not Know about Sex and Cardiac Disease, Journal of Biomedicine and Biotechnology, 10.1155/2010/562051, 2010, (1-11), . Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G and Butler J (2009) The Sympathetic Nervous System in Heart Failure, Journal of the American College of Cardiology, 10.1016/j.jacc.2009.05.015, 54:19, (1747-1762), Online publication date: 1-Nov-2009. Dorn G and Liggett S (2009) Mechanisms of Pharmacogenomic Effects of Genetic Variation within the Cardiac Adrenergic Network in Heart Failure, Molecular Pharmacology, 10.1124/mol.109.056572, 76:3, (466-480), Online publication date: 1-Sep-2009. Lymperopoulos A and Koch W (2009) AUTONOMIC PHARMACOLOGY Pharmacology and Therapeutics, 10.1016/B978-1-4160-3291-5.50013-5, (115-139), . Kim I, Tilley D, Chen J, Salazar N, Whalen E, Violin J and Rockman H (2008) β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation, Proceedings of the National Academy of Sciences, 10.1073/pnas.0804745105, 105:38, (14555-14560), Online publication date: 23-Sep-2008. Gourine A, Spyer K and Gourine A (2014) β-blockers: acting in the brain but healing the heart, Expert Review of Cardiovascular Therapy, 10.1586/14779072.6.7.913, 6:7, (913-915), Online publication date: 1-Aug-2008. Kaumann A and Molenaar P (2008) The low-affinity site of the β1-adrenoceptor and its relevance to cardiovascular pharmacology, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2008.03.009, 118:3, (303-336), Online publication date: 1-Jun-2008. Shuang W, Shiying F, Fengqi L, Renhai Q, Lanfeng W, Zhuqin L and Xu W (2008) Use of a high thoracic epidural analgesia for treatment of end-stage congestive heart failure secondary to coronary artery disease, International Journal of Cardiology, 10.1016/j.ijcard.2007.07.150, 125:2, (283-285), Online publication date: 1-Apr-2008. Frantz R, Lowes B, Grayburn P, White M, Krause-Steinrauf H, Krishnan V, Uyeda L and Burnett J (2007) Baseline and Serial Neurohormones in Patients With Congestive Heart Failure Treated With and Without Bucindolol: Results of the Neurohumoral Substudy of the Beta-Blocker Evaluation of Survival Study (BEST), Journal of Cardiac Failure, 10.1016/j.cardfail.2007.03.007, 13:6, (437-444), Online publication date: 1-Aug-2007. Kaye D and Krum H (2007) Drug discovery for heart failure: a new era or the end of the pipeline?, Nature Reviews Drug Discovery, 10.1038/nrd2219, 6:2, (127-139), Online publication date: 1-Feb-2007. Rochais F, Vilardaga J, Nikolaev V, Bünemann M, Lohse M and Engelhardt S (2007) Real-time optical recording of β1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol, Journal of Clinical Investigation, 10.1172/JCI30012, 117:1, (229-235), Online publication date: 2-Jan-2007. McCamish M and Izumi R (2006) Perspectives on development of a combination pharmacogenomic diagnostic and drug product, Pharmacogenomics, 10.2217/14622416.7.7.1045, 7:7, (1045-1049), Online publication date: 1-Oct-2006. Biolo A, Rosa A, Mazzotti N, Martins S, Belló-Klein A, Rohde L and Clausell N (2006) The role of adrenergic receptor polymorphisms in heart failure, Brazilian Journal of Medical and Biological Research, 10.1590/S0100-879X2006001000003, 39:10, (1281-1290), Online publication date: 1-Oct-2006. Münch G, Rosport K, Baumgartner C, Li Z, Wagner S, Bültmann A and Ungerer M (2006) Functional alterations after cardiac sodium-calcium exchanger overexpression in heart failure, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.01324.2005, 291:2, (H488-H495), Online publication date: 1-Aug-2006. Liggett S, Mialet-Perez J, Thaneemit-Chen S, Weber S, Greene S, Hodne D, Nelson B, Morrison J, Domanski M, Wagoner L, Abraham W, Anderson J, Carlquist J, Krause-Steinrauf H, Lazzeroni L, Port J, Lavori P and Bristow M (2006) A polymorphism within a conserved β 1 -adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure , Proceedings of the National Academy of Sciences, 10.1073/pnas.0509937103, 103:30, (11288-11293), Online publication date: 25-Jul-2006. Huang R, Listerman J, Goring J, Giesberg C, Nading M and Butler J (2007) Beta‐Blocker Therapy for Heart Failure: Should the Therapeutic Target Be Dose or Heart Rate Reduction?, Congestive Heart Failure, 10.1111/j.1527-5299.2006.05477.x, 12:4, (206-210), Online publication date: 1-Jul-2006. Cooke G (2006) Pharmacogenetics of multigenic disease: Heart disease as an example, Vascular Pharmacology, 10.1016/j.vph.2005.07.011, 44:2, (66-74), Online publication date: 1-Feb-2006. Jweied E, McKinney R, Walker L, Brodsky I, Geha A, Massad M, Buttrick P and de Tombe P (2005) Depressed cardiac myofilament function in human diabetes mellitus, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00638.2005, 289:6, (H2478-H2483), Online publication date: 1-Dec-2005. Recchia F and Giacca M (2005) Targeted Uptake-1 Carrier to Rescue the Failing Heart, Circulation Research, 97:9, (847-849), Online publication date: 28-Oct-2005.Münch G, Rosport K, Bültmann A, Baumgartner C, Li Z, Laacke L and Ungerer M (2005) Cardiac Overexpression of the Norepinephrine Transporter Uptake-1 Results in Marked Improvement of Heart Failure, Circulation Research, 97:9, (928-936), Online publication date: 28-Oct-2005. Adamson P (2005) Ambulatory Hemodynamics in Patients With Chronic Heart Failure: Implications for Volume Management in Elderly Patients, The American Journal of Geriatric Cardiology, 10.1111/j.1076-7460.2005.02596.x, 14:5, (236-241), Online publication date: 1-Sep-2005. Carmona-Bernal C, Quintana-Gallego E, Villa-Gil M, Sánchez-Armengol A, Martínez-Martínez A and Capote F (2005) Brain Natriuretic Peptide in Patients With Congestive Heart Failure and Central Sleep Apnea, Chest, 10.1378/chest.127.5.1667, 127:5, (1667-1673), Online publication date: 1-May-2005. Wacker J, Pasch T, Schaub M and Zaugg M (2005) Perioperative Strategien zur Regulierung des SympathikotonusStrategies for perioperative sympatho-modulation, Der Anaesthesist, 10.1007/s00101-005-0826-1, 54:4, (303-318), Online publication date: 1-Apr-2005. Schillinger W, Hermann H and Hasenfu� G (2004) Differenzialtherapie der HerzinsuffizienzDifferential therapy of heart failure?Which drug for which patient?, Der Internist, 10.1007/s00108-004-1290-8, 45:12, (1378-1387), Online publication date: 1-Dec-2004. Taylor M and Bristow M (2007) The Emerging Pharmacogenomics of the β‐Adrenergic Receptors, Congestive Heart Failure, 10.1111/j.1527-5299.2004.02019.x, 10:6, (281-288), Online publication date: 1-Nov-2004. Kaye D, Smirk B, Finch S, Williams C and Esler M (2004) Interaction between cardiac sympathetic drive and heart rate in heart failure, Journal of the American College of Cardiology, 10.1016/j.jacc.2004.07.058, 44:10, (2008-2015), Online publication date: 1-Nov-2004. Weston C (2004) Pharmacogenetics and cardiovascular disease management, Hospital Medicine, 10.12968/hosp.2004.65.10.16608, 65:10, (594-598), Online publication date: 1-Oct-2004. Adamson P, Abraham W, Love C and Reynolds D (2004) The evolving challenge of chronic heart failure management, Journal of the American College of Cardiology, 10.1016/j.jacc.2004.04.061, 44:7, (1354-1357), Online publication date: 1-Oct-2004. Adamson P and Germany R (2004) Therapy interactions in chronic heart failure: synergies and asynergies of medication and device interventions, Drug Discovery Today: Therapeutic Strategies, 10.1016/j.ddstr.2004.08.025, 1:2, (135-141), Online publication date: 1-Oct-2004. Zaugg M, Schulz C, Wacker J and Schaub M (2004) Sympatho-modulatory therapies in perioperative medicine, British Journal of Anaesthesia, 10.1093/bja/aeh158, 93:1, (53-62), Online publication date: 1-Jul-2004. Olson E (2004) A decade of discoveries in cardiac biology, Nature Medicine, 10.1038/nm0504-467, 10:5, (467-474), Online publication date: 1-May-2004. Singh B (2004) β-Blockers and Calcium Channel Blockers as Antiarrhythmic Drugs Cardiac Electrophysiology, 10.1016/B0-7216-0323-8/50103-2, (918-931), . Muchada R (2004) Perioperative b-adrenergic blocking drugs: from concept to applications Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E., 10.1007/978-88-470-2189-1_7, (759-770), . Kass D (2003) β-receptor polymorphisms: heart failure's crystal ball, Nature Medicine, 10.1038/nm1003-1260, 9:10, (1260-1262), Online publication date: 1-Oct-2003. March 4, 2003Vol 107, Issue 8 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000054530.87613.36PMID: 12615784 Originally publishedMarch 4, 2003 Keywordsreceptors, adrenergic, betanervous system, sympatheticreceptors, adrenergic, alphaheart failurePDF download Advertisement
Referência(s)